Today: 18 January 2026
Subscribe
Browse Category

FDA News News 2 January 2026 - 18 January 2026

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

New York, January 18, 2026, 06:30 EST — Market closed Pfizer Inc (PFE) shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters. (Investing)…
18 January 2026
····
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

New York, Jan 17, 2026, 10:03 ET — Market closed. Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication. The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to…
17 January 2026
····
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

NEW YORK, Jan 16, 2026, 21:08 EST — Market closed. Shares of Merck & Co (MRK.N) dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded. The drop came as investors digested a Reuters report revealing some drugmakers’ unease over the FDA Commissioner’s…
17 January 2026
····
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

New York, January 16, 2026, 17:39 EST — After-hours Eli Lilly (LLY.N) shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch,…
17 January 2026
····
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

New York, January 16, 2026, 05:24 EST — Premarket Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97. These shifts are crucial since Lilly’s valuation now hinges on the outlook for its upcoming obesity drugs and how…
16 January 2026
···
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

New York, Jan 15, 2026, 18:09 (ET) — After-hours update. Shares of Boston Scientific Corp (NYSE: BSX) dropped roughly 4% Thursday following its deal to acquire blood-clot treatment company Penumbra. Boston Scientific’s stock slipped $3.75, closing near $90.03 in late U.S. trading. Meanwhile, Penumbra (NYSE: PEN) surged around 12%, reaching $350.49. Boston Scientific announced it will pay $374 per Penumbra…
16 January 2026
···
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 16:43 (EST) — After-hours Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns…
15 January 2026
···
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

New York, Jan 14, 2026, 11:40 AM EST — Regular session Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning. (U.S. Food and Drug Administration) The label change is significant because it…
14 January 2026
····
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

New York, Jan 14, 2026, 08:52 EST — Premarket NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide…
14 January 2026
····
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

New York, Jan 13, 2026, 18:23 EST — After-hours Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound. (Reuters) The label shift…
14 January 2026
···
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as…
13 January 2026
···
Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

NEW YORK, January 2, 2026, 2:30 PM ET — Regular session Corcept Therapeutics Incorporated shares were up 5.7% at $36.77 on Friday afternoon, after a sharp selloff earlier in the week tied to a U.S. regulatory setback for its experimental drug relacorilant. The bounce matters because the FDA’s decision hit what investors had seen as a key growth driver beyond…
2 January 2026
····
1 2 3 … 5

Stock Market Today

  • Dutch Bros Price Outlook 2026-2030: Q3 Beat, Acquisition, Expansion
    January 18, 2026, 7:17 AM EST. Dutch Bros shares rose 0.24% in the last month after a 22.1% surge the prior month, trading roughly 27% below its Feb. 18, 2025 1-year high. In Q3, the coffee chain beat expectations with EPS of $0.19 and revenue of $423.6 million, up 25.2% year over year. On Jan. 14, Dutch Bros completed its first acquisition, buying Clutch Coffee Bar and converting all 20 North Carolina units to Dutch Bros locations. The company now runs about 950 stores in 18 states, far smaller than Dunkin (9,000+) and Starbucks (domestic ~16,500). It pursues a fortressing strategy to flood markets and lift efficiency. For 2026, Dutch Bros plans 175 new stores after opening 160+ in 2025, with 30+ openings per quarter for the past 13 quarters. Long-range forecasts from 24/7 Wall St. outline assumptions through 2030.
Go toTop